Send to

Choose Destination
Am J Trop Med Hyg. 2019 Jul;101(1):116-122. doi: 10.4269/ajtmh.18-0852.

Determination of Benznidazole in Human Dried Blood Spots by Liquid Chromatography-Mass Spectrometry to Monitor Adherence to Trypanosoma cruzi Infection Treatment in Infants and Children.

Author information

University of California, San Diego, La Jolla, California.
Boston University School of Medicine, Boston, Massachusetts.
Unidad de Investigación Clínica Montevideo (UNICEM), Montevideo, Uruguay.
Ministerio de Salud Pública de la Provincia de Tucumán, Tucumán, Argentina.
Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina.
Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben," Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Administracion Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbran" (ANLIS), Buenos Aires, Argentina.
School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana.


Medication adherence is critical to the effectiveness of benznidazole (BZ) therapy for the treatment of Chagas disease. Assessing BZ adherence using traditional plasma sampling methods presents numerous challenges in resource-limited settings. Dried blood spot (DBS) sampling of BZ can be used to overcome logistical barriers and provides a less invasive method for assessing BZ levels. A BZ DBS assay using liquid chromatography-tandem mass spectrometry was developed and applied to a clinical study of infants and children being treated with BZ for Trypanosoma cruzi infection in Argentina. The assay was validated over a concentration range of 9.8-5,000 ng/mL. Inter-assay and intra-assay measures ranged from -2.9% to 2.7% and 0.5% to 8.3% for accuracy and from 3.5% to 12% and 1.6% to 13.6% for precision, respectively. The mean recovery of BZ was greater than 91%. Partitioning ratios for DBSs/plasma ranged from 0.95 to 1.02. A cohort of 10 infants and six children with T. cruzi infection being treated with BZ had median BZ concentrations of 1.2 (IQR 0.29, 2.14) µg/mL with seven of 65 (11%) samples above the BZ treatment goal of 3 μg/mL for adults. The reported DBS assay is a simple and accurate method for the quantitative measurement of BZ that can be applied to facilitate urgently needed clinical studies of BZ for the treatment of Chagas disease and assess BZ adherence in resource-limited settings.

[Available on 2020-07-01]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center